Every 8-K that GeoVax Labs, Inc. New (GOVX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow GOVX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GOVX filings page.
GeoVax Labs, Inc. (GOVX) reported that it has appealed a Nasdaq delisting determination related to the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) and has been granted a hearing before a Nasdaq Hearings Panel on October 13, 2026. The hearing request stays any suspension or delisting action for now, so GeoVax’s common stock is expected to continue trading on The Nasdaq Capital Market under the symbol GOVX at least through the hearing and any extension period granted.
The company states it will present a plan to regain and maintain compliance while continuing to advance its key programs, including GEO-MVA, an MVA-based mpox and smallpox vaccine being prepared for a pivotal Phase 3 trial under an expedited regulatory pathway, and Gedeptin, a gene-directed enzyme prodrug therapy for head and neck cancer being advanced into combination and earlier-line settings. GeoVax also highlights its broader MVA vaccine platform, biodefense and global health focus, and ongoing pursuit of strategic partnerships and funding.
GeoVax Labs, Inc. (GOVX) reports that Nasdaq has determined to delist its common stock after the company failed to maintain the $1.00 per share minimum bid price for 30 consecutive business days from July 16 through August 26, 2026, violating Nasdaq Listing Rule 5550(a)(2). Because GeoVax implemented a 1-for-25 reverse stock split on January 12, 2026, it is not eligible for the usual 180‑day cure period. The company had already been notified it did not meet the $2,500,000 stockholders’ equity requirement under Listing Rule 5550(b). Trading is expected to be suspended on September 8, 2026 unless GeoVax timely requests a hearing by September 3, 2026, which it plans to do. The stock will continue trading during the appeal, but there is no assurance of a favorable outcome or that listing compliance will be regained.
GeoVax Labs, Inc. (GOVX) entered into a warrant exercise inducement agreement with an existing institutional investor. The investor agreed to immediately exercise warrants to purchase 5,697,628 shares of common stock at $0.64 per share, providing gross cash proceeds of approximately $3,646,482 before fees and expenses.
In exchange, GeoVax issued new unregistered warrants to purchase up to 11,395,256 additional shares at $0.64 per share, exercisable for five years after shareholder approval is obtained. GeoVax will pay A.G.P./Alliance Global Partners a 7.0% cash fee on the gross proceeds and reimburse up to $40,000 of legal expenses. The company plans to use net proceeds for working capital and general corporate purposes and has agreed to file a Form S-1 resale registration and to seek stockholder approval by October 29, 2026.
GeoVax Labs, Inc. reported results for the quarter and six months ended June 30, 2026 and outlined progress on its lead programs. The company is preparing a pivotal GEO-MVA immunobridging study under an expedited regulatory pathway supported by Scientific Advice from the European Medicines Agency, with initiation planned in the second half of 2026. GeoVax is also advancing its Gedeptin gene-directed enzyme prodrug therapy in combination immunotherapy strategies and holds an exclusive intellectual property license from Emory University covering Gedeptin with immune checkpoint inhibitors.
For the three months ended June 30, 2026, GeoVax reported a net loss of $4,426,578, or $0.97 per share, versus $5,369,783, or $8.74 per share, a year earlier. For the six months, net loss was $9,688,499, or $2.94 per share, compared with $10,727,434, or $19.72 per share, in 2025. No revenue was recognized in 2026 following termination of the BARDA COVID-19 vaccine contract in 2025, versus $852,282 and $2,489,145 of government contract revenue in the prior-year quarter and six-month period. Research and development expenses were $3,110,508 for the quarter and $7,013,971 year-to-date, down from $4,728,998 and $10,083,586, mainly due to reduced GEO-CM04S1 COVID-19 vaccine activities after a May 2026 portfolio reprioritization. General and administrative expenses were $1,331,564 for the quarter and $2,700,982 for six months, compared with $1,542,190 and $3,229,635, reflecting lower investor relations and stock-based compensation costs.
As of June 30, 2026, GeoVax reported cash and cash equivalents of $3,143,000, similar to $3,086,000 at December 31, 2025. Total assets were $4,643,000, with total liabilities of $2,882,000 and stockholders’ equity of $1,761,000. Common shares outstanding increased to 7,369,243 from 1,732,147 at year-end. The company’s strategic focus now centers on GEO-MVA for mpox and smallpox and Gedeptin for solid tumors, following the decision to discontinue active development of the GEO-CM04S1 COVID-19 vaccine candidate.
GeoVax Labs, Inc. received a notice from Nasdaq on July 7, 2026 that it is not in compliance with the $2,500,000 minimum stockholders’ equity requirement under Nasdaq Listing Rule 5550(b)(1), and it also does not meet the alternative market value or net income standards. The company has 45 calendar days, until August 21, 2026, to submit a compliance plan, after which Nasdaq Staff may grant up to a 180-day extension. Trading of the company’s common stock under the symbol GOVX on the Nasdaq Capital Market continues for now, while GeoVax evaluates options and prepares a plan; there is a risk of eventual delisting if compliance is not regained.
GeoVax Labs reported results from its annual shareholder meeting. Stockholders elected seven directors, ratified Wipfli LLP as independent auditor for the year ending December 31, 2026, and approved executive compensation on an advisory basis, including holding future say‑on‑pay votes every three years.
As of the April 20, 2026 record date, GeoVax had 2,892,570 shares of common stock outstanding and received proxies for 1,288,684 shares. Shareholders also approved three proposals under Nasdaq listing rules allowing issuance of up to 865,804, 1,269,316 and 1,702,986 shares of common stock upon exercise of previously issued warrants to institutional investors.
GeoVax Labs, Inc. entered into a private placement with institutional investors for approximately $3 million in gross proceeds, issuing 2,027,027 pre-funded warrants and 4,054,054 common warrants priced at $1.4799 per pre-funded warrant and accompanying common warrants.
The pre-funded warrants are exercisable immediately at $0.0001/share until fully exercised, while the common warrants, split into Series A and Series B, are exercisable immediately at $1.48/share with five-year and 18‑month terms, respectively. Net proceeds of about $2.7 million are earmarked for working capital and general corporate purposes.
The unregistered securities were issued under Section 4(a)(2) and Rule 506 of Regulation D, with A.G.P./Alliance Global Partners receiving a 7% cash fee plus expense reimbursements as placement agent. Warrant exercises are subject to a beneficial ownership cap of 4.99%, or 9.99% at the holder’s option.
GeoVax Labs reported a first quarter 2026 net loss of $5.3 million, similar to the $5.4 million loss a year earlier. Revenue fell to zero from $1.6 million in first quarter 2025 after termination of its BARDA/RRPV government contract for the GEO-CM04S1 COVID-19 program.
Research and development expenses declined to $3.9 million from $5.4 million, and general and administrative costs fell to $1.4 million from $1.7 million. Cash and cash equivalents were $1.3 million as of March 31, 2026, down from $3.1 million at December 31, 2025, with stockholders’ equity at $0.5 million.
Operationally, GeoVax highlighted plans to initiate an EMA-supported Phase 3 immunobridging trial for its GEO-MVA mpox/smallpox vaccine in the second half of 2026 and continued positioning of its Gedeptin® immuno-oncology platform, including an exclusive license from Emory University covering combinations with immune checkpoint inhibitors.
GeoVax Labs, Inc. entered into a warrant inducement transaction with institutional investors, who agreed to immediately exercise existing warrants to purchase 501,144 shares of common stock for gross cash proceeds of approximately $595,000, before fees and expenses.
In return, the investors will receive new unregistered warrants to purchase up to 1,002,288 shares of common stock at an exercise price of $1.65 per share. The new warrants will become exercisable after shareholder approval of the underlying shares and will expire five years after that approval date. GeoVax engaged A.G.P./Alliance Global Partners as exclusive financial advisor, paying a 7.0% cash fee on gross proceeds and reimbursing up to $40,000 of legal expenses.
GeoVax Labs, Inc. reported 2025 results showing a smaller annual loss alongside lower research spending as it advanced its GEO-MVA mpox/smallpox vaccine toward a pivotal Phase 3 trial planned for the second half of 2026.
For the year ended December 31, 2025, net loss was $21.5 million, or $22.40 per share, improving from a net loss of $25.0 million, or $120.46 per share, in 2024. Revenue from a government contract related to the BARDA/RRPV Project NextGen award was $2.5 million, down from $4.0 million after BARDA terminated the contract for convenience.
Research and development expenses fell to $18.1 million from $23.7 million, mainly due to discontinued BARDA-related costs and lower GEO-CM04S1 and Gedeptin spending. General and administrative expenses increased to $6.0 million from $5.4 million, driven by higher personnel, investor relations, patent, and stock-based compensation costs. GeoVax ended 2025 with $3.1 million in cash and equivalents and total assets of $6.3 million, compared with $5.5 million in cash and $8.2 million in total assets a year earlier.
GeoVax Labs, Inc. entered into a warrant inducement agreement with institutional investors, leading to the immediate cash exercise of existing warrants for 634,658 shares of common stock at a reduced exercise price of $1.36 per share, generating approximately $863,000 in gross proceeds.
In exchange, investors will receive new unregistered warrants to purchase up to 1,269,316 additional shares at $1.36 per share, exercisable after stockholder approval and expiring five years later. The company plans to use net proceeds for working capital and general corporate purposes, pay a 7.0% cash fee to its financial advisor, and seek stockholder approval by May 21, 2026.
GeoVax Labs, Inc. entered into definitive agreements for a registered direct offering of 432,902 shares of common stock or pre-funded warrants at $2.31 per share (or $2.30999 per pre-funded warrant), together with a concurrent private placement of Series A-1 and A-2 common warrants.
The company expects gross proceeds of about $1 million and net proceeds of approximately $865,000, and plans to use the cash for working capital, general corporate purposes and to advance its product candidates. The deal includes 432,902 Series A-1 and 432,902 Series A-2 warrants at a $2.31 exercise price, exercisable after stockholder approval, and a repricing of 236,000 existing warrants down to $2.31 per share.
GeoVax Labs, Inc. approved and implemented a 1-for-25 reverse stock split of its common stock effective upon filing a Certificate of Amendment on January 9, 2026. Every twenty-five shares of existing common stock were automatically combined into one share of new common stock, with the par value per share remaining $0.001.
No fractional shares were issued; any fractional amounts were rounded up to the next whole share. The company states that each stockholder’s percentage ownership and proportional voting power remain essentially the same apart from minor changes from rounding, and the rights and privileges attached to the common stock are substantially unaffected.
GeoVax Labs, Inc. (GOVX) reported the results of a special stockholder meeting held on November 26, 2025. Stockholders representing 14,125,083 of the company’s 29,705,360 issued and outstanding common shares as of September 30, 2025, were present by proxy.
Stockholders approved a proposal, required under Nasdaq listing rules, to allow the issuance of up to 11,904,768 shares of common stock upon exercise of common stock purchase warrants that were issued to certain institutional investors in a September 30, 2025 private placement. The proposal received 5,806,374 votes for, 946,094 against, and 870,973 abstentions, with 6,501,642 broker non-votes.
They also approved an amendment to the Certificate of Incorporation to implement a reverse stock split of the issued and outstanding common stock at a ratio between 1-for-10 and 1-for-25, with the exact ratio to be set by the Board of Directors. This proposal received 11,850,760 votes for, 2,158,471 against, and 115,852 abstentions.
GeoVax Labs, Inc. filed a current report to note that it released a press release covering its operating results for the quarter ended September 30, 2025. The company states that this press release, dated November 13, 2025, is furnished as Exhibit 99.1 to the report.
The filing also includes standard forward-looking statement language, explaining that projections and expectations are subject to risks and uncertainties, and that actual results may differ from current views. The report is signed on behalf of GeoVax Labs by its Chief Financial Officer, Mark W. Reynolds.
GeoVax Labs, Inc. filed an 8-K reporting a securities offering and related materials. The company engaged a placement agent and agreed to pay a cash fee equal to 7.0% of the gross proceeds plus reimbursement of certain expenses and legal fees. The Shares were offered under a Prospectus Supplement to an S-3 registration statement declared effective March 13, 2024 (File No. 333-277585). The company will issue accompanying Common Warrants and intends to issue the Warrant Shares pursuant to exemptions under Section 4(a)(2) and/or Rule 506(b) of Regulation D. Legal opinion and form agreements and exhibits are filed or incorporated by reference, and a press release dated September 30, 2025 announcing pricing is attached as an exhibit.